Clinical trials: CABG in Low EF
Coronary Artery Bypass, Cardiopulmonary Bypass
Role of Glutamine as Myocardial Protector in Elective On-Pump CABG Surgery With Low EF
Coronary artery disease has the highest mortality rate worldwide and coronary artery bypass grafting (CABG) is the most common cardiac surgery performed in patients with coronary artery disease to revascularize the heart.
- Conditions
- Coronary Artery Bypass, Cardiopulmonary Bypass, Coronary Artery Disease
- Trial name
- NCT04560309
- Testing
- L-alanyl-L-glutamine dipeptide
- Where
- Indonesia
- Volunteers
- 60 people
- Sponsor
- National Cardiovascular Center Harapan Kita Hospital Indonesia
Coronary Artery Disease, Coronary Artery Disease (CAD)
Surgical Versus Percutaneous Revascularization in Patients With Reduced Left Ventricular Function (STICH 3.0-NL)
This randomized multicenter trial compares coronary artery bypass grafting (CABG) with percutaneous coronary intervention (PCI) in 358 patients with ischemic left ventricular dysfunction and multivessel coronary disease.
- Conditions
- Coronary Artery Disease, Coronary Artery Disease (CAD), Multivessel Coronary Artery Disease, CABG
- Trial name
- STICH 3*0-NL (NCT07269366)
- Testing
- CABG, PCI
- Where
- Netherlands
- Volunteers
- 358 people
- Sponsor
- University Medical Center Groningen
CABG in Low EF
Early Outcome in Unstable Angina Patients With Low EF After CABG
Coronary artery bypass grafting (CABG) among patients with reduced myocardial function remains a surgical challenge despite improvement in surgical technique, myocardial protection and postoperative care.
- Trial name
- NCT03276624
- Testing
- CABG
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Assiut University